Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow

Journal of Clinical Oncology

Volumn 21, Issue 23, 2003, Pages 4428-4438

  Stevenson, James P ^a   Rosen, Mark ^a   Sun, Weijing ^a   Gallagher, Maryann ^a   Haller, Daniel G ^a   Vaughn, David ^a   Giantonio, Bruce ^a   Zimmer, Ross ^a   Petros, William P ^a   Stratford, Michael ^a   Chaplin, David ^a   Young, Scott L ^a   Schnall, Mitchell ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; ANTINEOPLASTIC AGENT; COMBRETASTATIN A 4; COMBRETASTATIN A-4; CONTRAST MEDIUM; STILBENE DERIVATIVE;

ADVANCED CANCER; ARTICLE; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DYSPNEA; HEADACHE; HUMAN; HYPOTENSION; HYPOXIA; INJECTION SITE PAIN; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSORY NEUROPATHY; SYNCOPE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLOOD FLOW; VOMITING; ADULT; AGED; AREA UNDER THE CURVE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHASE 1 CLINICAL TRIAL; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CONTRAST MEDIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0642307227     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.986     Document Type: Article

References (41)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31, 1995
2. Denekamp J: Angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196, 1993
3. Hill SA, Lonergan SJ, Denekamp J, et al: Vinca alkaloids: Antivascular effects in a murine tumor. Eur J Cancer 29A:1320-1324, 1993
4. Hill SA, Sampson LE, Chaplin DJ: Antivascular approaches to solid tumor therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 63:119-123, 1995
5. Pettit GR, Singh SB, Hamel E, et al: Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45:209-211, 1989
6. Woods JA, Hadfield JA, Pettit GR, et al: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71:705-711, 1995
7. Pettit GR, Temple C, Narayanan VL, et al: Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309, 1995
8. Tozer GM, Kanthou C, Parkins CS, et al: The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83:21-38, 2002
9. Dark GD, Hill SA, Prise VE, et al: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834, 1997
10. Iyer S, Chaplin DJ, Rosenthal DS, et al: Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 58:4510-4514, 1998
11. Grostos K, Holwell SE, McGown AT, et al: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81:1318-1327, 1999
12. Tozer GM, Prise VE, Wilson J, et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumor and normal tissues. Cancer Res 59:1626-1634, 1999
13. Beauregard DA, Thelwall PE, Chaplin DJ, et al: Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumor perfusion and energetic status. Br J Cancer 77:1761-1767, 1998
14. Oxigene, Inc: Combretastatin A4 phosphate investigator's brochure. Boston, MA, Oxigene Inc, 1999
15. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
16. Stratford MRL, Dennis MF: Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 721:77-85, 1999
17. Evelhoch JL: Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254-259, 1999
18. Tofts PS, Kermode AG: Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn Reson Med 17:357-367, 1991
19. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999
20. Dowlati A, Robertson K, Cooney M, et al: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416, 2002
21. Stark DB, Fletcher WS: Severe tumor pain associated with injection of vinblastine sulfate (NSC-49843). Cancer Chemother Rep 50:281-282, 1966
22. Kornek GV, Kornfehl H, Hejna M, et al: Acute tumor pain in patients with head and neck cancer treated with vinorelbine. J Natl Cancer Inst 88:1593, 1996
23. Mross K, Berdel WE, Feibig HH, et al: Clinical and pharmacologic phase I study of Cemadotin-HCL (LU103793), a novel antimitotic peptide, given as a 24-hour infusion in patients with advanced cancer: A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society. Ann Oncol 9:1323-1330, 1998
24. Stevenson JP, Sun W, Gallagher M, et al: Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res 8:2524-2529, 2002
25. Rustin GJS, Galbraith SM, Taylor NJ, et al: Combretastatin A4 phosphate selectively targets vasculature in animal and human tumors. Clin Cancer Res 5:3732s, 1999 (suppl)
26. Belotti D, Vergani V, Drudis T, et al: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996
27. Hu E, Ko R, Koda R, et al: Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother Pharmacol 26:359-364, 1990
28. Platts SH, Falcone JC, Holton WT, et al: Alteration of microtubule polymerization modulates arteriolar vasomotor tone. Am J Physiol 277:H100-H106, 1999
29. Griggs J, Hesketh R, Smith GA, et al: Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 84:832-835, 2001
30. Ito H, Okafuji T, Suzuki T: Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. Heart Vessels 10:178-184, 1995
31. Kohn S, Fradis M, Podoshin L, et al: Endothelial injury of capillaries in the stria vascularis of guinea pigs treated with cisplatin and gentamicin. Ultrastruct Pathol 21:289-299, 1997
32. Padhani AR, Husband JE: Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56:607-620, 2001
33. Donahue KM, Krouwer HG, Rand SD, et al: Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 43:845-853, 2000
34. Brasch R, Turetschek K: MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report. Eur J Radiol 34:148-155, 2000
35. Davis DW, Mullani N, Hess KR, et al: Quantitative analysis of tumor vascular targeting: Effects of endostatin in a phase I clinical trial. Clin Cancer Res 7:3711s, 2001 (abstr 286)
36. Mundhenke C, Thomas JP, Neider R, et al: Endothelial cell kinetics in skin wounds and tumors of patients receiving endostatin. Proc Am Soc Clin Oncol 20:70a, 2001 (abstr 277)
37. Mayr NA, Yuh WT, Arnholt JC, et al: Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12:1027-1033, 2000
38. Galbraith SM, Lodge MA, Taylor NJ, et al: Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132-142, 2002
39. Nelkin BD, Ball DW: Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of medullary thyroid carcinoma. Oncol Rep 8:157-160, 2001
40. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with Combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys 42:899-903, 1998
41. Grosios K, Loadman PM, Swaine DJ, et al: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine adenocarcinoma. Anticancer Res 20:229-233, 2000